{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:30:19Z","timestamp":1792096219649,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2051,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1093\/annonc\/mdu008","type":"journal-article","created":{"date-parts":[[2014,3,9]],"date-time":"2014-03-09T01:13:12Z","timestamp":1394327592000},"page":"843-847","source":"Crossref","is-referenced-by-count":40,"title":["Fracture incidence after 3 years of aromatase inhibitor therapy"],"prefix":"10.1016","volume":"25","author":[{"given":"B.","family":"Bouvard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Souli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hopp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Georgin-Mege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mesgouez-Nebout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jadaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tuchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vinchon-Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Audran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chappard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1093\/annonc\/mdu008_bb0010","doi-asserted-by":"crossref","first-page":"vi12","DOI":"10.1093\/annonc\/mdr371","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Aebi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0015","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine- responsive early breast cancer: update of study BIG 1\u201398","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0025","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","article-title":"Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper","volume":"23","author":"Rizzoli","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdu008_bb0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","article-title":"High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy","volume":"23","author":"Bouvard","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0035","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor- induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0040","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr2565","article-title":"Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial","volume":"12","author":"Markopoulos","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdu008_bb0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO- FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0050","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0055","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00432-012-1233-z","article-title":"Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial","volume":"138","author":"Markopoulos","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(96)00102-0","article-title":"Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study","volume":"19","author":"Riis","year":"1996","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdu008_bb0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdu008_bb0070","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdq541","article-title":"Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial","volume":"22","author":"Eastell","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1359\/jbmr.2005.20.1.131","article-title":"Risk factors for a first-incident radiographic vertebral fracture in women > or =65 years of age: the study of osteoporotic fractures","volume":"20","author":"Nevitt","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdu008_bb0080","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu008_bb0085","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","article-title":"A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International","volume":"62","author":"Reid","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1093\/annonc\/mdu008_bb0090","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1093\/annonc\/mdu008_bb0095","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1359\/JBMR.050104","article-title":"Effect of alendronate on the age- specific incidence of symptomatic osteoporotic fractures","volume":"20","author":"Hochberg","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdu008_bb0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu008_bb0105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341936497X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341936497X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/4\/843\/16703274\/mdu008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T20:05:13Z","timestamp":1625169913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341936497X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S092375341936497X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu008","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}